company background image
ALPN

Alpine Immune SciencesNasdaqGM:ALPN Stock Report

Market Cap

US$254.9m

7D

7.1%

1Y

42.1%

Updated

23 Sep, 2021

Data

Company Financials +
ALPN fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

ALPN Overview

Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases.

Price History & Performance

Summary of all time highs, changes and price drops for Alpine Immune Sciences
Historical stock prices
Current Share PriceUS$10.66
52 Week HighUS$7.21
52 Week LowUS$16.37
Beta1.73
1 Month Change15.87%
3 Month Change9.56%
1 Year Change42.13%
3 Year Change65.27%
5 Year Changen/a
Change since IPO11.62%

Recent News & Updates

Shareholder Returns

ALPNUS BiotechsUS Market
7D7.1%0.07%-0.5%
1Y42.1%31.0%37.5%

Return vs Industry: ALPN exceeded the US Biotechs industry which returned 28.4% over the past year.

Return vs Market: ALPN exceeded the US Market which returned 36.2% over the past year.

Price Volatility

Is ALPN's price volatile compared to industry and market?
ALPN volatility
ALPN Beta1.73
Industry Beta1.03
Market Beta1

Stable Share Price: ALPN is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: ALPN's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
200757Mitch Goldhttps://www.alpineimmunesciences.com

Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for B cell-mediated autoimmune/inflammatory diseases. The company has a collaboration agreement with AbbVie Ireland Unlimited Company for the research, development, and commercialization of ALPN-101; and Adaptimmune Therapeutics plc to develop next-generation SPEAR T cell products.

Alpine Immune Sciences Fundamentals Summary

How do Alpine Immune Sciences's earnings and revenue compare to its market cap?
ALPN fundamental statistics
Market CapUS$254.93m
Earnings (TTM)-US$34.15m
Revenue (TTM)US$17.95m

14.2x

P/S Ratio

-7.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ALPN income statement (TTM)
RevenueUS$17.95m
Cost of RevenueUS$40.28m
Gross Profit-US$22.33m
ExpensesUS$11.82m
Earnings-US$34.15m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-1.45
Gross Margin-124.37%
Net Profit Margin-190.22%
Debt/Equity Ratio23.4%

How did ALPN perform over the long term?

See historical performance and comparison

Valuation

Is Alpine Immune Sciences undervalued compared to its fair value and its price relative to the market?

5.82x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate ALPN's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate ALPN's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: ALPN is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: ALPN is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ALPN's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ALPN is overvalued based on its PB Ratio (5.8x) compared to the US Biotechs industry average (3.2x).


Future Growth

How is Alpine Immune Sciences forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

-30.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ALPN is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ALPN is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ALPN is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ALPN's revenue is expected to decline over the next 3 years (-12.7% per year).

High Growth Revenue: ALPN's revenue is forecast to decline over the next 3 years (-12.7% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ALPN's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Alpine Immune Sciences performed over the past 5 years?

-32.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ALPN is currently unprofitable.

Growing Profit Margin: ALPN is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ALPN is unprofitable, and losses have increased over the past 5 years at a rate of 32% per year.

Accelerating Growth: Unable to compare ALPN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ALPN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4.9%).


Return on Equity

High ROE: ALPN has a negative Return on Equity (-77.92%), as it is currently unprofitable.


Financial Health

How is Alpine Immune Sciences's financial position?


Financial Position Analysis

Short Term Liabilities: ALPN's short term assets ($139.7M) exceed its short term liabilities ($60.2M).

Long Term Liabilities: ALPN's short term assets ($139.7M) exceed its long term liabilities ($55.7M).


Debt to Equity History and Analysis

Debt Level: ALPN's debt to equity ratio (23.4%) is considered satisfactory.

Reducing Debt: ALPN's debt to equity ratio has increased from 1.1% to 23.4% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ALPN has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: ALPN has sufficient cash runway for 1.7 years if free cash flow continues to grow at historical rates of 6% each year.


Dividend

What is Alpine Immune Sciences's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ALPN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ALPN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ALPN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ALPN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ALPN's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.3yrs

Average management tenure


CEO

Mitch Gold (53 yo)

5.25yrs

Tenure

US$1,384,012

Compensation

Dr. Mitchell H. Gold, also known as Mitch, M.D., has been Executive Chairman and Chief Executive Officer at Alpine Immune Sciences Inc. since January 2015 and June 2016 respectively. Dr. Gold served as the...


CEO Compensation Analysis

Compensation vs Market: Mitch's total compensation ($USD1.38M) is about average for companies of similar size in the US market ($USD1.09M).

Compensation vs Earnings: Mitch's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: ALPN's management team is considered experienced (2.3 years average tenure).


Board Members

Experienced Board: ALPN's board of directors are considered experienced (4.2 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Alpine Immune Sciences, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Alpine Immune Sciences, Inc.
  • Ticker: ALPN
  • Exchange: NasdaqGM
  • Founded: 2007
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$254.933m
  • Shares outstanding: 23.91m
  • Website: https://www.alpineimmunesciences.com

Number of Employees


Location

  • Alpine Immune Sciences, Inc.
  • 188 East Blaine Street
  • Suite 200
  • Seattle
  • Washington
  • 98102
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/09/23 23:07
End of Day Share Price2021/09/23 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.